poisar

Stocks · News reference

Novo Nordisk Showcases CagriSema Trial Gains and Wegovy Food Noise Reductions Ahead of FDA Decision

BenzingaVandana Singh

Novo Nordisk unveils Phase 3 CagriSema weight-loss data and real-world Wegovy food-noise reductions at ObesityWeek 2026 in Washington, D.C.

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Globenewswire IncPrecedence Research

    Pharmaceutical Market to Reach USD 3.20 Trillion by 2035 as Obesity and Oncology Drugs Lead Growth and U.S. Pricing Deals and Tariffs Reshape Manufacturing

    The global pharmaceutical market is valued at USD 1.88 trillion in 2026 and is projected to reach USD 3.20 trillion by 2035 at a CAGR of 6.10%. Growth is concentrated in obesity and oncology therapies, with U.S. pricing deals and Section 232 tariffs reshaping manufacturing. North America holds 42% of the market, while companies with strong positions in GLP-1 medicines and cancer therapies are growing significantly faster than the market.

  2. Fiscal.ai

    Team Novo Nordisk to Rebrand as Team Novo in 2027

    The professional cycling team composed of riders living with type 1 diabetes will be rebranded as Team Novo starting in 2027, with Novo Nordisk continuing as the title sponsor.

  3. The Motley FoolBrendan Coffey

    Johnson & Johnson vs. Novo Nordisk: Steady Uptrend vs. Flat Revenue

    Johnson & Johnson demonstrates strong revenue growth with consistent quarter-over-quarter increases, while Novo Nordisk struggles with largely flat revenue despite a notable spike in Q1 2026. JNJ's diverse portfolio of 28+ billion-dollar products contrasts with Novo Nordisk's challenges as competitors catch up in the GLP-1 weight loss market.